Clinical Report: Cytokine Patterns During Microaxial Pump Support in Cardiogenic Shock
Overview
This retrospective, single-center study evaluated serial IL-1β, IL-6, IL-8, and TNF-α measurements in adults with cardiogenic shock receiving microaxial flow pump support. The supplied article material describes the study rationale, eligibility, and sampling methods, but does not provide cohort results or outcome data; therefore, it does not establish whether cytokine trajectories identified a high-risk profile or added prognostic information.
Background
Cardiogenic shock involves circulatory failure and may also include a systemic inflammatory response associated with myocardial ischemia and reperfusion. Cytokines such as IL-1β, IL-6, IL-8, and TNF-α have been associated in the article context with myocardial depression, vasoplegia, endothelial dysfunction, and microcirculatory impairment. Current shock assessment frameworks emphasize clinical staging and hemodynamic and metabolic measures, while infection markers such as CRP and procalcitonin may also rise in shock without microbiological evidence of infection. The study was designed to examine whether longitudinal cytokine measurements during microaxial pump support relate to infection markers and clinical outcomes.
Data Highlights
Study feature
Details provided
Design and setting
Retrospective, single-center cohort at University Hospital of Marburg, Germany
Screening period
January 2021 to December 2023
Population
Adults aged 18 years or older with cardiogenic shock at SCAI stage C or above at device implantation, treated with an Impella microaxial pump
Exclusions
Support under 24 hours, concomitant VA-ECMO, no serial measurements of the specified cytokines, or Impella 5.5 implantation
Sampling schedule
Baseline at implantation and 24, 72, 120, and 168 hours (T0–T4), when samples were available
Biomarkers and assay
Serum IL-1β, IL-6, IL-8, and TNF-α measured using chemiluminescent immunoassays on the IMMULITE 2000 XPi system
Results available in supplied material
No sample size, cytokine results, or clinical outcome estimates provided
Key Findings
The study was designed to assess cytokine trajectories in patients with cardiogenic shock receiving microaxial flow pump support in a real-world setting.
Eligible patients had SCAI stage C or higher shock at implantation; patients receiving concomitant VA-ECMO or Impella 5.5 were excluded.
Serial measurements were planned at implantation and 24, 72, 120, and 168 hours, with sampling dependent on specimen availability.
The measured cytokines were IL-1β, IL-6, IL-8, and TNF-α, quantified from serum using chemiluminescent immunoassays.
The authors’ stated hypothesis was that early, sustained cytokine elevation would identify a high-risk inflammatory phenotype and provide prognostic information beyond conventional hemodynamic indices; the supplied material does not report whether this hypothesis was supported.
Related source context describes cardiogenic shock as heterogeneous and identifies SCAI staging as a framework for risk stratification; it does not provide findings that validate cytokine profiling in this cohort.
Clinical Implications
The supplied material supports describing serial cytokine profiling as the study’s investigational approach, not as an established clinical decision tool. Because cohort results and outcome analyses are not included, no conclusion about prognostic performance or clinical use can be drawn from the provided information.
Conclusion
The article describes a longitudinal cytokine study in microaxial pump-supported cardiogenic shock, with sampling through seven days and a focus on inflammatory phenotype and outcomes. Results are absent from the supplied source material, so the proposed high-risk profile cannot be assessed here.
Related Resources & Content
SCAI SHOCK Stage Classification Expert Consensus Update, JACC, 2022 — A Review and Incorporation of Validation Studies
Journal of Cardiac Failure, year not provided — Microaxial Flow Pump Use in Different Phenotypes of Cardiogenic Shock—a Secondary Analysis of the DanGer Shock Trial
Journal of Cardiac Failure, year not provided — VA-ECMO Support in Cardiogenic Shock: A Post Hoc Analysis of cDPP3 Levels and Their Impact on Outcomes in the ADRECMO Cohort
Clinical Research in Cardiology — Timing of IABP initiation and its impact on outcomes in acute myocardial infarction with cardiogenic shock: insights from a bi-center retrospective study
Frontiers in Cardiovascular Medicine — Patterns of temporary mechanical circulatory support, escalation, de-escalation and outcomes in cardiogenic shock
SCAI SHOCK Stage Classification Expert Consensus Update: A Review and Incorporation of Validation Studies
Microaxial Flow Pump Use in Different Phenotypes of Cardiogenic Shock—a Secondary Analysis of the DanGer Shock Trial
VA-ECMO Support in Cardiogenic Shock: A Post Hoc Analysis of cDPP3 Levels and Their Impact on Outcomes in the ADRECMO Cohort
SCAI SHOCK Stage Classification Expert Consensus Update: A Review and Incorporation of Validation Studies: This statement was endorsed by the American College of Cardiology (ACC), American College of Emergency Physicians (ACEP), American Heart Association (AHA), European Society of Cardiology (ESC) Association for Acute Cardiovascular Care (ACVC), International Society for Heart and Lung Transplantation (ISHLT), Society of Critical Care Medicine (SCCM), and Society of Thoracic Surgeons (STS) in December 2021. | JACC
PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock | New England Journal of Medicine
Phoenix Children’s has promoted four division chiefs from within the health system to lead vital areas including pediatric intensive care, cardiovascular intensive care, nephrology and physical medicine and rehabilitation.
Patients with greater frailty showed larger improvements in health-related quality of life, while cardiovascular treatment effects did not differ significantly across frailty categories.
